- Home
- INDV vs GLPG Comparison
INDV vs GLPG Comparison
Compare INDV & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDV
- GLPG
- Stock Information
- Founded
- INDV 1994
- GLPG 1999
- Country
- INDV United States
- GLPG Belgium
- Employees
- INDV N/A
- GLPG N/A
- Industry
- INDV Biotechnology: Pharmaceutical Preparations
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- INDV Health Care
- GLPG Health Care
- Exchange
- INDV Nasdaq
- GLPG Nasdaq
- Market Cap
- INDV 1.9B
- GLPG 2.1B
- IPO Year
- INDV N/A
- GLPG 2005
- Fundamental
- Price
- INDV $24.98
- GLPG $33.36
- Analyst Decision
- INDV Strong Buy
- GLPG Sell
- Analyst Count
- INDV 4
- GLPG 4
- Target Price
- INDV $23.75
- GLPG $25.33
- AVG Volume (30 Days)
- INDV 2.1M
- GLPG 255.3K
- Earning Date
- INDV 10-23-2025
- GLPG 10-29-2025
- Dividend Yield
- INDV N/A
- GLPG N/A
- EPS Growth
- INDV N/A
- GLPG N/A
- EPS
- INDV 0.42
- GLPG N/A
- Revenue
- INDV $1,173,000,000.00
- GLPG $323,674,692.00
- Revenue This Year
- INDV N/A
- GLPG N/A
- Revenue Next Year
- INDV $3.00
- GLPG N/A
- P/E Ratio
- INDV $59.99
- GLPG N/A
- Revenue Growth
- INDV 2.27
- GLPG 5.43
- 52 Week Low
- INDV $7.33
- GLPG $22.36
- 52 Week High
- INDV $25.00
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- INDV 80.77
- GLPG 59.82
- Support Level
- INDV $23.59
- GLPG $30.88
- Resistance Level
- INDV $25.00
- GLPG $33.25
- Average True Range (ATR)
- INDV 0.68
- GLPG 0.75
- MACD
- INDV -0.18
- GLPG -0.02
- Stochastic Oscillator
- INDV 98.96
- GLPG 97.25
About INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.